Aktienanalyse zu MannKind Corp (MNKD)MNKDMannKind Corp

MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

MannKind Corp (MNKD) is not a good buy right now due to a current price of $3.29 and a concerning RSI of 28.057, indicating oversold conditions. The stock has seen a significant decline of 41.25% year-to-date, and hedge funds are selling, with a 337.78% increase in selling activity over the last quarter. The main risk is the negative net income trend, with a reported loss of $19 million in Q2 2026.

2 analysts cover MNKD: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.25.